Cargando…
Gemcitabine and XCT790, an ERRα inverse agonist, display a synergistic anticancer effect in pancreatic cancer
Pancreatic cancer (PC) is one of the most fatal and chemoresistant malignancies with a poor prognosis. The current therapeutic options for PC have not achieved satisfactory results due to drug resistance. Therefore, it is urgent to develop novel treatment strategies with enhanced efficacy. This stud...
Autores principales: | Liu, Shi-lei, Liang, Hai-bin, Yang, Zi-yi, Cai, Chen, Wu, Zi-you, Wu, Xiang-song, Dong, Ping, Li, Mao-lan, Zheng, Lei, Gong, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8795805/ https://www.ncbi.nlm.nih.gov/pubmed/35165514 http://dx.doi.org/10.7150/ijms.68404 |
Ejemplares similares
-
The Estrogen-Related Receptor α Inverse Agonist
XCT 790 Is a Nanomolar Mitochondrial Uncoupler
por: Eskiocak, Banu, et al.
Publicado: (2014) -
Identification of Selective ERRγ Inverse Agonists
por: Kim, Jina, et al.
Publicado: (2016) -
Molecular dynamics of the ERRγ ligand-binding domain bound with agonist and inverse agonist
por: Sasidharan, Santanu, et al.
Publicado: (2023) -
Modulation of Autophagy by a Small Molecule Inverse Agonist of ERRα Is Neuroprotective
por: Suresh, S. N., et al.
Publicado: (2018) -
Novel endocrine therapeutic strategy in endometrial carcinoma targeting estrogen-related receptor α by XCT790 and siRNA
por: Sun, PengMing, et al.
Publicado: (2018)